Last reviewed · How we verify
LAR Lanreotide
Lanreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of growth hormone and other hormones.
Lanreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of growth hormone and other hormones. Used for Acromegaly, Gastroenteropancreatic neuroendocrine tumors (GEP-NETs), Carcinoid syndrome.
At a glance
| Generic name | LAR Lanreotide |
|---|---|
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Drug class | Somatostatin analog |
| Target | Somatostatin receptors (SSTR2, SSTR5) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Lanreotide mimics somatostatin, a natural inhibitory hormone, by binding to somatostatin receptors (particularly SSTR2 and SSTR5) on neuroendocrine tumor cells and normal endocrine tissues. This binding suppresses the release of growth hormone, insulin-like growth factor-1 (IGF-1), and other hormones, thereby controlling hormone-related symptoms and slowing tumor growth in neuroendocrine malignancies.
Approved indications
- Acromegaly
- Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
- Carcinoid syndrome
Common side effects
- Diarrhea
- Abdominal pain
- Nausea
- Cholelithiasis (gallstones)
- Fatigue
- Injection site reactions
Key clinical trials
- A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (PHASE1)
- A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET (PHASE3)
- Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors (PHASE3)
- A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide (PHASE4)
- A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve) (PHASE2)
- 177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors (PHASE2)
- Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients (PHASE4)
- Acromegaly Combination Treatment Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LAR Lanreotide CI brief — competitive landscape report
- LAR Lanreotide updates RSS · CI watch RSS
- Memorial Sloan Kettering Cancer Center portfolio CI